Request for Nominations for Voting Members on Public Advisory Committees, 7973-7974 [E6-2071]
Download as PDF
<![CDATA[
7973
Federal Register / Vol. 71, No. 31 / Wednesday, February 15, 2006 / Notices
ANNUAL BURDEN ESTIMATES
Instrument
Number of
respondents
Number of
responses per
respondent
Average
burden hours
per response
Total burden
hours
Community-Based Abstinence Education Program Announcement ...............
400
1
9
3,600
Estimated Total Annual Burden
Hours 3,600.
In compliance with the requirements
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Administration for Children and
Families is soliciting public comment
on the specific aspects of the
information collection described above.
Copies of the proposed collection of
information can be obtained and
comments may be forwarded by writing
to the Administration for Children and
Families, Office of Administration,
Office of Information Services, 370
L’Enfant Promenade, SW., Washington,
DC 20447, Attn: ACF Reports Clearance
Officer. E-mail address:
infocollection@acf.hhs.gov. All requests
should be identified by the title of the
information collection.
The Department specifically requests
comments on: (a) Whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
Dated: February 9, 2006.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 06–1402 Filed 2–14–06; 8:45 am]
BILLING CODE 4184–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Request for Nominations for Voting
Members on Public Advisory
Committees
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is requesting
nominations for voting members to
serve on the Allergenic Products
Advisory Committee, Blood Products
Advisory Committee, Cellular, Tissue
and Gene Therapies Advisory
Committee, Transmissible Spongiform
Encephalopathies Advisory Committee,
and the Vaccines and Related Biological
Products Advisory Committee in the
Center for Biologics Evaluation and
Research (CBER). Nominations will be
accepted for vacancies that will or may
occur through December 31, 2006.
FDA has a special interest in ensuring
that women, minority groups, and
individuals with disabilities are
adequately represented on advisory
committees and, therefore, encourages
nominations of qualified candidates
from these groups.
DATES: Because scheduled vacancies
occur on various dates throughout each
year, no cutoff date is established for the
receipt of nominations. However, when
possible, nominations should be
received at least 6 months before the
date of scheduled vacancies for each
year, as indicated in this notice.
ADDRESSES: All nominations and
curricula vitae should be sent to the
contact person listed in the FOR FURTHER
INFORMATION CONTACT section of this
document.
FOR FURTHER INFORMATION CONTACT:
Donald Jehn, Division of Scientific
Advisors and Consultants, Center for
Biologics Evaluation and Research
(HFM–71), Food and Drug
Administration, 1401 Rockville Pike,
Rockville, MD 20852–1448, 301–827–
0314, e-mail: donald.jehn@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: FDA is
requesting nominations of voting
members with appropriate expertise for
vacancies listed as follows:
TABLE 1.
No. of Vacancies
Approximate Date Members are Needed
Allergenic Products Advisory Committee—allergy, immunology, pediatrics, internal medicine, biochemistry, statistics, and related scientific fields
1
1
As soon as possible
August 31, 2006
Blood Products Advisory Committee—clinical and administrative medicine, hematology, immunology, blood banking, surgery, internal medicine, biochemistry, engineering, statistics, biological and physical sciences, biotechnology, computer technology, epidemiology, consumer advocacy, sociology/ethics, and other related professions
cprice-sewell on PROD1PC66 with NOTICES
Advisory Committee and Expertise Needed to Fill Vacancies
2
1
As soon as possible
September 30, 2006
VerDate Aug<31>2005
13:17 Feb 14, 2006
Jkt 208001
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
E:\FR\FM\15FEN1.SGM
15FEN1
7974
Federal Register / Vol. 71, No. 31 / Wednesday, February 15, 2006 / Notices
TABLE 1.—Continued
Advisory Committee and Expertise Needed to Fill Vacancies
No. of Vacancies
Approximate Date Members are Needed
Cellular, Tissue, and Gene Therapies Advisory Committee—cellular therapies, tissue transplantation, gene
transfer therapies and xenotransplantation including biostatistics, bioethics, hematology/oncology, human tissues
and transplantation, reproductive medicine, general medicine and various medical specialties including surgery
and oncology, immunology, virology, molecular biology,
cell biology, developmental biology, tumor biology, biochemistry, rDNA technology, nuclear medicine, gene
therapy, infectious diseases, and cellular kinetics
2
March 31, 2006
Transmissible Spongiform Encephalopathies Advisory
Committee—clinical and administrative medicine, hematology, virology, neurovirology, neurology, infectious diseases, immunology, transfusion medicine, surgery, internal medicine, biochemistry, biostatistics, epidemiology,
biological and physical sciences, consumer advocacy,
sociology/ethics, and other related professions
3
As soon as possible
Vaccines and Related Biological Products Advisory Committee—immunology, molecular biology, rDNA, virology,
bacteriology, epidemiology, biostatistics, allergy, preventive medicine, infectious diseases, pediatrics, microbiology, biochemistry, and other related scientific fields
4
As soon as possible
D. Transmissible Spongiform
Encephalopathies Advisory Committee
I. Functions
A. Allergenic Products Advisory
Committee
The committee reviews and evaluates
available data concerning the safety,
effectiveness, and adequacy of labeling
of marketed and investigational
allergenic biological products or
materials that are administered to
humans for the diagnosis, prevention, or
treatment of allergies and allergic
diseases.
The committee reviews and evaluates
available scientific data concerning the
safety of products which may be at risk
for transmission of spongiform
encephalopathies having an impact on
the public health.
E. Vaccines and Related Biological
Products Advisory Committee
B. Blood Products Advisory Committee
The committee reviews and evaluates
available data concerning the safety,
effectiveness, and appropriate use of
blood and products derived from blood
and serum or biotechnology which are
intended for use in the diagnosis,
prevention, or treatment of human
diseases.
The committee reviews and evaluates
data concerning the safety,
effectiveness, and appropriate use of
vaccines and related biological products
which are intended for use in the
prevention, treatment, or diagnosis of
human diseases.
II. Qualifications
cprice-sewell on PROD1PC66 with NOTICES
C. Cellular, Tissue and Gene Therapies
Advisory Committee
The committee reviews and evaluates
available data relating to the safety,
effectiveness, and appropriate use of
human cells, human tissues, gene
transfer therapies and
xenotransplantation products which are
intended for transplantation,
implantation, infusion, and transfer in
the prevention and treatment of a broad
spectrum of human diseases and in
reconstruction, repair, or replacement of
tissues for various conditions.
VerDate Aug<31>2005
13:17 Feb 14, 2006
Jkt 208001
Persons nominated for membership
on the committees shall have adequately
diversified experience appropriate to
the work of the committee in such fields
as clinical and administrative medicine,
engineering, biological and physical
sciences, statistics, and other related
professions. The nature of specialized
training and experience necessary to
qualify the nominee as an expert
suitable for appointment may include
experience in medical practice,
teaching, and/or research relevant to the
field of activity of the committee. The
particular need for vacancies on each
committee for the calendar year 2006 is
shown in Table 1 of this document. The
term of office is up to 4 years,
depending on the appointment date.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
III. Nomination Procedures
Any interested person may nominate
one or more qualified persons for
membership on one or more of the
advisory committees. Self-nominations
are also accepted. Nominations shall
include the name of the committee, a
complete curriculum vitae of each
nominee, current business address and
telephone number, and shall state that
the nominee is aware of the nomination,
is willing to serve as a member (name
of committee(s) must be specified), and
appears to have no conflict of interest
that would preclude membership. FDA
will ask the potential candidates to
provide detailed information concerning
such matters as financial holdings,
employment, and research grants and/or
contracts to permit evaluation of
possible sources of conflict of interest.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14
relating to advisory committees.
Dated: February 7, 2006.
Jason Brodsky,
Acting Associate Commissioner for External
Relations.
[FR Doc. E6–2071 Filed 2–14–06; 8:45 am]
BILLING CODE 4160–01–S
E:\FR\FM\15FEN1.SGM
15FEN1
]]>Agencies
[Federal Register Volume 71, Number 31 (Wednesday, February 15, 2006)]
[Notices]
[Pages 7973-7974]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-2071]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Request for Nominations for Voting Members on Public Advisory
Committees
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is requesting
nominations for voting members to serve on the Allergenic Products
Advisory Committee, Blood Products Advisory Committee, Cellular, Tissue
and Gene Therapies Advisory Committee, Transmissible Spongiform
Encephalopathies Advisory Committee, and the Vaccines and Related
Biological Products Advisory Committee in the Center for Biologics
Evaluation and Research (CBER). Nominations will be accepted for
vacancies that will or may occur through December 31, 2006.
FDA has a special interest in ensuring that women, minority groups,
and individuals with disabilities are adequately represented on
advisory committees and, therefore, encourages nominations of qualified
candidates from these groups.
DATES: Because scheduled vacancies occur on various dates throughout
each year, no cutoff date is established for the receipt of
nominations. However, when possible, nominations should be received at
least 6 months before the date of scheduled vacancies for each year, as
indicated in this notice.
ADDRESSES: All nominations and curricula vitae should be sent to the
contact person listed in the FOR FURTHER INFORMATION CONTACT section of
this document.
FOR FURTHER INFORMATION CONTACT: Donald Jehn, Division of Scientific
Advisors and Consultants, Center for Biologics Evaluation and Research
(HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville,
MD 20852-1448, 301-827-0314, e-mail: donald.jehn@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: FDA is requesting nominations of voting
members with appropriate expertise for vacancies listed as follows:
Table 1.
------------------------------------------------------------------------
Advisory Committee and
Expertise Needed to Fill No. of Vacancies Approximate Date
Vacancies Members are Needed
------------------------------------------------------------------------
Allergenic Products Advisory 1 As soon as possible
Committee--allergy, 1 August 31, 2006
immunology, pediatrics,
internal medicine,
biochemistry, statistics,
and related scientific
fields
------------------------------------------------------------------------
Blood Products Advisory 2 As soon as possible
Committee--clinical and 1 September 30, 2006
administrative medicine,
hematology, immunology,
blood banking, surgery,
internal medicine,
biochemistry, engineering,
statistics, biological and
physical sciences,
biotechnology, computer
technology, epidemiology,
consumer advocacy, sociology/
ethics, and other related
professions
------------------------------------------------------------------------
[[Page 7974]]
Cellular, Tissue, and Gene 2 March 31, 2006
Therapies Advisory
Committee--cellular
therapies, tissue
transplantation, gene
transfer therapies and
xenotransplantation
including biostatistics,
bioethics, hematology/
oncology, human tissues and
transplantation,
reproductive medicine,
general medicine and various
medical specialties
including surgery and
oncology, immunology,
virology, molecular biology,
cell biology, developmental
biology, tumor biology,
biochemistry, rDNA
technology, nuclear
medicine, gene therapy,
infectious diseases, and
cellular kinetics
------------------------------------------------------------------------
Transmissible Spongiform 3 As soon as possible
Encephalopathies Advisory
Committee--clinical and
administrative medicine,
hematology, virology,
neurovirology, neurology,
infectious diseases,
immunology, transfusion
medicine, surgery, internal
medicine, biochemistry,
biostatistics, epidemiology,
biological and physical
sciences, consumer advocacy,
sociology/ethics, and other
related professions
------------------------------------------------------------------------
Vaccines and Related 4 As soon as possible
Biological Products Advisory
Committee--immunology,
molecular biology, rDNA,
virology, bacteriology,
epidemiology, biostatistics,
allergy, preventive
medicine, infectious
diseases, pediatrics,
microbiology, biochemistry,
and other related scientific
fields
------------------------------------------------------------------------
I. Functions
A. Allergenic Products Advisory Committee
The committee reviews and evaluates available data concerning the
safety, effectiveness, and adequacy of labeling of marketed and
investigational allergenic biological products or materials that are
administered to humans for the diagnosis, prevention, or treatment of
allergies and allergic diseases.
B. Blood Products Advisory Committee
The committee reviews and evaluates available data concerning the
safety, effectiveness, and appropriate use of blood and products
derived from blood and serum or biotechnology which are intended for
use in the diagnosis, prevention, or treatment of human diseases.
C. Cellular, Tissue and Gene Therapies Advisory Committee
The committee reviews and evaluates available data relating to the
safety, effectiveness, and appropriate use of human cells, human
tissues, gene transfer therapies and xenotransplantation products which
are intended for transplantation, implantation, infusion, and transfer
in the prevention and treatment of a broad spectrum of human diseases
and in reconstruction, repair, or replacement of tissues for various
conditions.
D. Transmissible Spongiform Encephalopathies Advisory Committee
The committee reviews and evaluates available scientific data
concerning the safety of products which may be at risk for transmission
of spongiform encephalopathies having an impact on the public health.
E. Vaccines and Related Biological Products Advisory Committee
The committee reviews and evaluates data concerning the safety,
effectiveness, and appropriate use of vaccines and related biological
products which are intended for use in the prevention, treatment, or
diagnosis of human diseases.
II. Qualifications
Persons nominated for membership on the committees shall have
adequately diversified experience appropriate to the work of the
committee in such fields as clinical and administrative medicine,
engineering, biological and physical sciences, statistics, and other
related professions. The nature of specialized training and experience
necessary to qualify the nominee as an expert suitable for appointment
may include experience in medical practice, teaching, and/or research
relevant to the field of activity of the committee. The particular need
for vacancies on each committee for the calendar year 2006 is shown in
Table 1 of this document. The term of office is up to 4 years,
depending on the appointment date.
III. Nomination Procedures
Any interested person may nominate one or more qualified persons
for membership on one or more of the advisory committees. Self-
nominations are also accepted. Nominations shall include the name of
the committee, a complete curriculum vitae of each nominee, current
business address and telephone number, and shall state that the nominee
is aware of the nomination, is willing to serve as a member (name of
committee(s) must be specified), and appears to have no conflict of
interest that would preclude membership. FDA will ask the potential
candidates to provide detailed information concerning such matters as
financial holdings, employment, and research grants and/or contracts to
permit evaluation of possible sources of conflict of interest.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14 relating to advisory committees.
Dated: February 7, 2006.
Jason Brodsky,
Acting Associate Commissioner for External Relations.
[FR Doc. E6-2071 Filed 2-14-06; 8:45 am]
BILLING CODE 4160-01-S
